← Leaderboards
Rong Tian
Brigham And Women'S Hospital
$29,765,984
Attributed
$32,151,627
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$32,151,627 · 12
By mechanism
R01$31,243,583 · 9
R21$540,748 · 1
K01$340,296 · 1
R13$27,000 · 1
Top collaborators
- Kevin D. O'Brien10 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Joanne S Ingwall$1,811,884
- Danny O. Jacobs$277,857
- Maryam M Javadpour$86,496
Others in their field
Top investigators on “Cardiac”
- Judith S Hochman · New York University School Of Medicine$110,228,771
- Anne Christine Gelijns · Icahn School Of Medicine At Mount Sinai$69,868,084
- Rose A Gubitosi-Klug · Case Western Reserve University$61,225,818
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$53,141,827
- Joseph C Wu · Stanford University$53,027,789
- Pamela Susan Douglas · Duke University$51,506,531
Research focus
CardiacHeartHeart FailureMetabolicMitochondriaMyocardialStressSignal TransductionMouse ModelMolecularMetabolismProductionResponseGlucoseHypertrophyHeart HypertrophyCellsProteinsHomeostasisEnergy MetabolismMediatingPreventOverexpressionMitochondrial Dysfunction
Grant awards (65)
2024 Cardiac Regulatory Mechanisms Gordon Research Conference and Seminar$27,000
R13 · FY2024 · HL · contact PI
Mechanistic Studies of NAD+/NADH in Human Heart Failure$749,718
R01 · FY2023 · HL
Mitochondrial metabolism and macrophage function post MI$696,227
R01 · FY2023 · HL · contact PI
Mechanistic Studies of NAD+/NADH in Human Heart Failure$181,823
R01 · FY2023 · HL
Mechanistic Studies of NAD+/NADH in Human Heart Failure$773,881
R01 · FY2022 · HL
Mitochondrial metabolism and macrophage function post MI$740,793
R01 · FY2022 · HL · contact PI
Energy metabolism and NAD+/NADH in Right Ventricular Failure$205,417
R01 · FY2022 · HL
Mechanistic Studies of NAD+/NADH in Human Heart Failure$773,881
R01 · FY2021 · HL
Mitochondrial metabolism and macrophage function post MI$740,793
R01 · FY2021 · HL · contact PI
Mitochondrial function and glycolytic switch in pathological cardiac hypertrophy$586,448
R01 · FY2021 · HL · contact PI
NAD+/NADH ratio, protein acetylation and mitochondrial function$773,891
R01 · FY2020 · HL · contact PI
Mechanistic Studies of NAD+/NADH in Human Heart Failure$773,881
R01 · FY2020 · HL
Mitochondrial metabolism and macrophage function post MI$740,793
R01 · FY2020 · HL · contact PI
Mitochondrial function and glycolytic switch in pathological cardiac hypertrophy$586,448
R01 · FY2020 · HL · contact PI
Mechanistic Studies of NAD+/NADH in Human Heart Failure$771,937
R01 · FY2019 · HL
NAD+/NADH ratio, protein acetylation and mitochondrial function$771,698
R01 · FY2019 · HL · contact PI
Mitochondrial function and glycolytic switch in pathological cardiac hypertrophy$586,448
R01 · FY2019 · HL · contact PI
NAD+/NADH ratio, protein acetylation and mitochondrial function$771,698
R01 · FY2018 · HL · contact PI
Fatty acid oxidation suppresses cardiac hypertrophy$695,040
R01 · FY2018 · HL · contact PI
Mitochondrial function and glycolytic switch in pathological cardiac hypertrophy$621,996
R01 · FY2018 · HL · contact PI
Fatty acid oxidation suppresses cardiac hypertrophy$67,077
R01 · FY2018 · HL · contact PI
Glucose And BCAA Metabolism in the Heart$774,754
R01 · FY2017 · HL · contact PI
NAD+/NADH ratio, protein acetylation and mitochondrial function$767,314
R01 · FY2017 · HL · contact PI
Fatty acid oxidation suppresses cardiac hypertrophy$697,615
R01 · FY2017 · HL · contact PI
Safety and Tolerability of the Nutritional Supplement, Nicotinamide Riboside, in Systolic Heart Failure$193,125
R21 · FY2017 · HL · contact PI
Glucose And BCAA Metabolism in the Heart$774,754
R01 · FY2016 · HL · contact PI
Fatty acid oxidation suppresses cardiac hypertrophy$689,659
R01 · FY2016 · HL · contact PI
Glucose And BCAA Metabolism in the Heart$763,132
R01 · FY2015 · HL · contact PI
Fatty acid oxidation suppresses cardiac hypertrophy$686,405
R01 · FY2015 · HL · contact PI
Isoform-specific function of y-AMPK in the heart.$520,861
R01 · FY2015 · HL · contact PI
Safety and Tolerability of the Nutritional Supplement, Nicotinamide Riboside, in Systolic Heart Failure$231,750
R21 · FY2015 · HL · contact PI
Safety and Tolerability of the Nutritional Supplement, Nicotinamide Riboside, in Systolic Heart Failure$115,873
R21 · FY2015 · HL · contact PI
Glucose And BCAA Metabolism in the Heart$774,754
R01 · FY2014 · HL · contact PI
Complex I Deficiency Triggered Acceleration of Heart Failure$613,712
R01 · FY2014 · HL · contact PI
Isoform-specific function of y-AMPK in the heart.$517,907
R01 · FY2014 · HL · contact PI
Complex I Deficiency Triggered Acceleration of Heart Failure$606,889
R01 · FY2013 · HL · contact PI
Isoform-specific function of y-AMPK in the heart.$501,198
R01 · FY2013 · HL · contact PI
Complex I Deficiency Triggered Acceleration of Heart Failure$628,556
R01 · FY2012 · HL · contact PI
Isoform-specific function of y-AMPK in the heart.$508,191
R01 · FY2012 · HL · contact PI
Complex I Deficiency Triggered Acceleration of Heart Failure$767,129
R01 · FY2011 · HL · contact PI
Cardiac metabolism and heart failure$457,427
R01 · FY2010 · HL · contact PI
Glycogen metabolism and PRKAG2 cardiomyopathy$410,130
R01 · FY2010 · HL · contact PI
AMP-activated protein kinase in hypertrophied hearts$402,965
R01 · FY2010 · HL · contact PI
Cardiac metabolism and heart failure$447,024
R01 · FY2009 · HL · contact PI
Glycogen metabolism and PRKAG2 cardiomyopathy$412,335
R01 · FY2009 · HL · contact PI
AMP-activated protein kinase in hypertrophied hearts$402,965
R01 · FY2009 · HL · contact PI
AMP-activated protein kinase in hypertrophied hearts$412,797
R01 · FY2008 · HL · contact PI
Glycogen metabolism and PRKAG2 cardiomyopathy$412,335
R01 · FY2008 · HL · contact PI
Glucose utilization in hypertrophied and failing hearts$341,736
R01 · FY2008 · HL · contact PI
Glycogen metabolism and PRKAG2 cardiomyopathy$420,750
R01 · FY2007 · HL · contact PI
AMP-activated protein kinase in hypertrophied hearts$412,797
R01 · FY2007 · HL · contact PI
Glucose utilization in hypertrophied and failing hearts$341,736
R01 · FY2007 · HL · contact PI
AMP-activated protein kinase in hypertrophied hearts$425,125
R01 · FY2006 · HL · contact PI
Glucose utilization in hypertrophied and failing hearts$351,943
R01 · FY2006 · HL · contact PI
Glucose utilization in hypertrophied and failing hearts$360,413
R01 · FY2005 · HL
AMP-activated protein kinase in hypertrophied hearts$389,250
R01 · FY2004 · HL
Glucose utilization in hypertrophied and failing hearts$360,413
R01 · FY2004 · HL
AMP-activated protein kinase in hypertrophied hearts$389,250
R01 · FY2003 · HL
AMP-activated protein kinase in hypertrophied hearts$389,063
R01 · FY2002 · HL
GLUCOSE UTILIZATION IN SENESCENT HEARTS$124,680
K01 · FY2002 · AG
AMP-activated protein kinase in hypertrophied hearts$386,531
R01 · FY2001 · HL
GLUCOSE UTILIZATION IN SENESCENT HEARTS$108,480
K01 · FY2001 · AG
GLUCOSE UTILIZATION IN HYPERTROPHIED AND FAILING HEARTS$55,730
R01 · FY2001 · HL
GLUCOSE UTILIZATION IN SENESCENT HEARTS$107,136
K01 · FY2000 · AG
GLUCOSE UTILIZATION IN HYPERTROPHIED AND FAILING HEARTS$58,150
R01 · FY2000 · HL